GlassScriptPhysician profile
Deanne J Threapleton
NPI 1851688865
$9,247.74
in general payments reported to CMS, 2019-2025
34 companies · $2,128 in 2025
The $2,128 reported for 2025 was more than what 94% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,792 · 2022: $2,055 · 2023: $1,013 · 2024: $1,260 · 2025: $2,128.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,401.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,400.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,114.59 | 2021-2025 | Proclaim, Octrode, Eterna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $964.93 | 2021-2025 | Relistor, Trulance |
| Collegium Pharmaceutical, INC. | $800.56 | 2021-2025 | Belbuca, Xtampza |
| Biohaven Pharmaceuticals, INC. | $711.85 | 2021 | |
| Abbvie INC. | $687.39 | 2021-2025 | |
| Pfizer INC. | $590.28 | 2021-2025 | |
| Lundbeck LLC | $505.04 | 2021-2025 | Vyepti |
| Amgen INC. | $433.07 | 2021-2025 | Aimovig, Krystexxa |
| Biohaven Pharmaceutical Holding Company LTD. | $420.70 | 2022 | |
| Scilex Pharmaceuticals INC. | $370.81 | 2021-2025 | Ztlido |
| Lilly USA, LLC | $360.51 | 2021-2023 | Reyvow, Emgality |
| Pacira Pharmaceuticals Incorporated | $274.10 | 2023-2025 | Zilretta, Iovera |
| Boston Scientific Corporation | $248.22 | 2022-2025 | Wavewriter Alpha Prime 16 |
| Vertex Pharmaceuticals Incorporated | $229.61 | 2024-2025 | |
| Axsome Therapeutics, INC. | $197.45 | 2025 | Symbravo |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $195.82 | 2021-2022 | |
| Bioventus LLC | $155.06 | 2021 | |
| Protega Pharmaceutials INC | $136.03 | 2025 | Roxybond |
| Azurity Pharmaceuticals, INC. | $93.05 | 2023-2025 | Horizant, Horizant |
| Biodelivery Sciences International, INC. | $83.54 | 2021 | |
| Arbor Pharmaceuticals, INC. | $74.53 | 2021 | |
| Stimwave Technologies Incorporated | $73.08 | 2021 | |
| Almatica Pharma LLC | $70.34 | 2021 | |
| Horizon Therapeutics Plc | $62.53 | 2022-2023 | Krystexxa |
| Novartis Pharmaceuticals Corporation | $58.35 | 2021 | |
| Grt US Holding, INC. | $58.14 | 2021 | |
| Pacira Therapeutics, INC. | $54.14 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $52.51 | 2022-2023 | Seglentis |
| Saluda Medical Americas, INC. | $46.72 | 2025 | Evoke |
| Averitas Pharma INC. | $43.18 | 2025 | Qutenza |
| Zimmer Biomet Holdings, INC. | $26.81 | 2024 | Gel-One Cross-Linked Hyaluronate |
| Uswm, LLC | $22.53 | 2022 | |
| Alnylam Pharmaceuticals INC. | $17.49 | 2025 | Givlaari |
| Virtus Pharmaceuticals LLC | $14.78 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deanne Threapleton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.